E-therapeutics Regulatory News (ETX)

e-Therapeutics plc ("e-Therapeutics" or the "Company")

Directorate Change

Oxford and Newcastle, UK, 5 January 2015 - Further to the announcement in September 2014 of Professor Oliver James' retirement as Chairman and as a Non-Executive Director of the Company, with effect from 31 December 2014, e-Therapeutics confirms that Professor Malcolm Young, Chief Executive Officer, has assumed the role of acting Chairman with effect from 1 January 2015.

Brad Hoy, Non-Executive Director, will Chair both the Remuneration and Audit Committees in the interim, and the Company expects that an additional Non-Executive Director will be appointed in due course. 

-Ends-

Contacts:

e-Therapeutics plc

Malcolm Young / Steve Medlicott

Tel: +44 (0) 7733 263 513

www.etherapeutics.co.uk

N+1 Singer

Aubrey Powell/ Jen Boorer

Tel: +44 (0) 20 7496 3155

www.n1singer.com

Instinctif Partners

Melanie Toyne Sewell / Emma Barlow

Tel: +44 (0) 20 7457 2020

Email: e-therapeutics@instinctif.com

About e-Therapeutics

e-Therapeutics is an AIM-quoted biotechnology company with a proprietary platform in network pharmacology, an innovative new approach to drug discovery based on advances in network science and chemical biology. The Company's discovery and development activity is focused in cancer and disorders of the nervous system. e-Therapeutics is based at sites in Oxford and Newcastle, UK. For more information about the Company please visit www.etherapeutics.co.uk.